Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

TXMD vs ANIP vs TEVA vs MCK vs CAH

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
TXMD
TherapeuticsMD, Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • US
Market Cap$23M
5Y Perf.-96.4%
ANIP
ANI Pharmaceuticals, Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • US
Market Cap$1.78B
5Y Perf.+155.8%
TEVA
Teva Pharmaceutical Industries Limited

Drug Manufacturers - Specialty & Generic

HealthcareNYSE • IL
Market Cap$41.93B
5Y Perf.+187.4%
MCK
McKesson Corporation

Medical - Distribution

HealthcareNYSE • US
Market Cap$92.15B
5Y Perf.+374.1%
CAH
Cardinal Health, Inc.

Medical - Distribution

HealthcareNYSE • US
Market Cap$43.59B
5Y Perf.+238.7%

TXMD vs ANIP vs TEVA vs MCK vs CAH — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
TXMD logoTXMD
ANIP logoANIP
TEVA logoTEVA
MCK logoMCK
CAH logoCAH
IndustryDrug Manufacturers - Specialty & GenericDrug Manufacturers - Specialty & GenericDrug Manufacturers - Specialty & GenericMedical - DistributionMedical - Distribution
Market Cap$23M$1.78B$41.93B$92.15B$43.59B
Revenue (TTM)$3M$883M$17.35B$403.43B$250.55B
Net Income (TTM)$302K$78M$1.56B$4.76B$1.56B
Gross Margin96.6%69.1%52.1%3.6%3.7%
Operating Margin-97.1%12.6%13.2%1.5%0.9%
Forward P/E9.2x14.5x19.3x17.9x
Total Debt$7M$325M$17.38B$7.39B$9.35B
Cash & Equiv.$5M$286M$3.56B$5.69B$3.87B

TXMD vs ANIP vs TEVA vs MCK vs CAHLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

TXMD
ANIP
TEVA
MCK
CAH
StockMay 20May 26Return
TherapeuticsMD, Inc. (TXMD)1003.6-96.4%
ANI Pharmaceuticals… (ANIP)100255.8+155.8%
Teva Pharmaceutical… (TEVA)100287.4+187.4%
McKesson Corporation (MCK)100474.1+374.1%
Cardinal Health, In… (CAH)100338.7+238.7%

Price return only. Dividends and distributions are not included.

Quick Verdict: TXMD vs ANIP vs TEVA vs MCK vs CAH

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: ANIP and CAH are tied at the top with 2 categories each (5-stock set) — the right choice depends on your priorities. Cardinal Health, Inc. is the stronger pick specifically for capital preservation and lower volatility and dividend income and shareholder returns. TXMD, TEVA, and MCK also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
TXMD
TherapeuticsMD, Inc.
The Defensive Pick

TXMD ranks third and is worth considering specifically for sleep-well-at-night.

  • Lower volatility, beta 0.51, Low D/E 26.2%, current ratio 1.92x
  • 10.8% margin vs CAH's 0.6%
Best for: sleep-well-at-night
ANIP
ANI Pharmaceuticals, Inc.
The Growth Play

ANIP has the current edge in this matchup, primarily because of its strength in growth exposure.

  • Rev growth 43.8%, EPS growth 419.2%, 3Y rev CAGR 40.8%
  • 43.8% revenue growth vs CAH's -1.9%
  • Lower P/E (9.2x vs 17.9x)
Best for: growth exposure
TEVA
Teva Pharmaceutical Industries Limited
The Momentum Pick

TEVA is the clearest fit if your priority is momentum.

  • +104.6% vs MCK's +4.6%
Best for: momentum
MCK
McKesson Corporation
The Long-Run Compounder

MCK is the clearest fit if your priority is long-term compounding.

  • 348.1% 10Y total return vs CAH's 160.8%
  • 5.7% ROA vs TXMD's 0.8%, ROIC 5.4% vs -11.4%
Best for: long-term compounding
CAH
Cardinal Health, Inc.
The Income Pick

CAH is the #2 pick in this set and the best alternative if income & stability and defensive is your priority.

  • Dividend streak 20 yrs, beta 0.03, yield 1.1%
  • Beta 0.03, yield 1.1%, current ratio 0.94x
  • Beta 0.03 vs TEVA's 1.13
  • 1.1% yield, 20-year raise streak, vs MCK's 0.4%, (2 stocks pay no dividend)
Best for: income & stability and defensive
See the full category breakdown
CategoryWinnerWhy
GrowthANIP logoANIP43.8% revenue growth vs CAH's -1.9%
ValueANIP logoANIPLower P/E (9.2x vs 17.9x)
Quality / MarginsTXMD logoTXMD10.8% margin vs CAH's 0.6%
Stability / SafetyCAH logoCAHBeta 0.03 vs TEVA's 1.13
DividendsCAH logoCAH1.1% yield, 20-year raise streak, vs MCK's 0.4%, (2 stocks pay no dividend)
Momentum (1Y)TEVA logoTEVA+104.6% vs MCK's +4.6%
Efficiency (ROA)MCK logoMCK5.7% ROA vs TXMD's 0.8%, ROIC 5.4% vs -11.4%

TXMD vs ANIP vs TEVA vs MCK vs CAH — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

TXMDTherapeuticsMD, Inc.
FY 2023
License
100.0%$1M
ANIPANI Pharmaceuticals, Inc.
FY 2024
Total Sales of Generics and Other
52.1%$320M
Sales of rare disease pharmaceutical products
37.4%$230M
Sales of Established Brands
10.5%$65M
TEVATeva Pharmaceutical Industries Limited
FY 2025
Product
84.6%$14.6B
Distribution Service
9.0%$1.6B
License
3.9%$678M
Product and Service, Other
2.5%$423M
MCKMcKesson Corporation
FY 2025
U.S. Pharmaceutical Segment
91.3%$327.7B
International Segment
4.1%$14.7B
Medical-Surgical Solutions Segment
3.2%$11.4B
Prescription Technology Solutions
1.5%$5.2B
CAHCardinal Health, Inc.
FY 2025
Pharmaceutical Member
91.9%$204.6B
GMPD
5.7%$12.6B
Other Operating Segment
2.4%$5.4B

TXMD vs ANIP vs TEVA vs MCK vs CAH — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLTXMDLAGGINGCAH

Income & Cash Flow (Last 12 Months)

TXMD leads this category, winning 4 of 6 comparable metrics.

MCK is the larger business by revenue, generating $403.4B annually — 144288.3x TXMD's $3M. TXMD is the more profitable business, keeping 10.8% of every revenue dollar as net income compared to CAH's 0.6%. On growth, TXMD holds the edge at +43.3% YoY revenue growth, suggesting stronger near-term business momentum.

MetricTXMD logoTXMDTherapeuticsMD, I…ANIP logoANIPANI Pharmaceutica…TEVA logoTEVATeva Pharmaceutic…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …
RevenueTrailing 12 months$3M$883M$17.3B$403.4B$250.5B
EBITDAEarnings before interest/tax-$2M$203M$3.3B$6.8B$3.2B
Net IncomeAfter-tax profit$302,000$78M$1.6B$4.8B$1.6B
Free Cash FlowCash after capex$2M$128M$1.2B$6.0B$4.4B
Gross MarginGross profit ÷ Revenue+96.6%+69.1%+52.1%+3.6%+3.7%
Operating MarginEBIT ÷ Revenue-97.1%+12.6%+13.2%+1.5%+0.9%
Net MarginNet income ÷ Revenue+10.8%+8.9%+9.0%+1.2%+0.6%
FCF MarginFCF ÷ Revenue+74.0%+14.5%+6.8%+1.5%+1.8%
Rev. Growth (YoY)Latest quarter vs prior year+43.3%+29.6%+2.3%+6.0%+11.0%
EPS Growth (YoY)Latest quarter vs prior year+118.9%+3.1%+72.2%+37.0%-19.5%
TXMD leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

ANIP leads this category, winning 3 of 6 comparable metrics.

At 25.3x trailing earnings, ANIP trades at a 16% valuation discount to TEVA's 30.0x P/E. On an enterprise value basis, ANIP's 9.0x EV/EBITDA is more attractive than MCK's 18.7x.

MetricTXMD logoTXMDTherapeuticsMD, I…ANIP logoANIPANI Pharmaceutica…TEVA logoTEVATeva Pharmaceutic…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …
Market CapShares × price$23M$1.8B$41.9B$92.1B$43.6B
Enterprise ValueMkt cap + debt − cash$25M$1.8B$55.8B$93.8B$49.1B
Trailing P/EPrice ÷ TTM EPS-10.58x25.27x30.01x29.25x28.72x
Forward P/EPrice ÷ next-FY EPS est.9.25x14.55x19.28x17.94x
PEG RatioP/E ÷ EPS growth rate0.75x
EV / EBITDAEnterprise value multiple8.99x17.65x18.74x16.01x
Price / SalesMarket cap ÷ Revenue13.21x2.02x2.43x0.26x0.20x
Price / BookPrice ÷ Book value/share0.85x3.29x5.34x
Price / FCFMarket cap ÷ FCF31.78x9.62x36.52x17.63x23.56x
ANIP leads this category, winning 3 of 6 comparable metrics.

Profitability & Efficiency

MCK leads this category, winning 4 of 9 comparable metrics.

MCK delivers a 3.0% return on equity — every $100 of shareholder capital generates $3 in annual profit, vs $1 for TXMD. TXMD carries lower financial leverage with a 0.26x debt-to-equity ratio, signaling a more conservative balance sheet compared to TEVA's 2.20x. On the Piotroski fundamental quality scale (0–9), TEVA scores 8/9 vs CAH's 6/9, reflecting strong financial health.

MetricTXMD logoTXMDTherapeuticsMD, I…ANIP logoANIPANI Pharmaceutica…TEVA logoTEVATeva Pharmaceutic…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …
ROE (TTM)Return on equity+1.1%+14.5%+20.7%+3.0%
ROA (TTM)Return on assets+0.8%+5.4%+3.9%+5.7%+2.8%
ROICReturn on invested capital-11.4%+11.2%+7.7%+5.4%+33.8%
ROCEReturn on capital employed-13.6%+9.9%+8.0%+30.5%+19.2%
Piotroski ScoreFundamental quality 0–966866
Debt / EquityFinancial leverage0.26x0.60x2.20x
Net DebtTotal debt minus cash$2M$40M$13.8B$1.7B$5.5B
Cash & Equiv.Liquid assets$5M$286M$3.6B$5.7B$3.9B
Total DebtShort + long-term debt$7M$325M$17.4B$7.4B$9.3B
Interest CoverageEBIT ÷ Interest expense-194.43x1.82x2.51x33.79x6.38x
MCK leads this category, winning 4 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

TEVA leads this category, winning 3 of 6 comparable metrics.

A $10,000 investment in MCK five years ago would be worth $38,689 today (with dividends reinvested), compared to $369 for TXMD. Over the past 12 months, TEVA leads with a +104.6% total return vs MCK's +4.6%. The 3-year compound annual growth rate (CAGR) favors TEVA at 58.4% vs TXMD's -19.7% — a key indicator of consistent wealth creation.

MetricTXMD logoTXMDTherapeuticsMD, I…ANIP logoANIPANI Pharmaceutica…TEVA logoTEVATeva Pharmaceutic…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …
YTD ReturnYear-to-date+21.8%+7.0%+16.3%-8.5%-9.5%
1-Year ReturnPast 12 months+45.7%+18.5%+104.6%+4.6%+22.0%
3-Year ReturnCumulative with dividends-48.2%+97.1%+297.5%+106.4%+127.3%
5-Year ReturnCumulative with dividends-96.3%+117.4%+246.2%+286.9%+235.7%
10-Year ReturnCumulative with dividends-99.5%+84.7%-28.3%+348.1%+160.8%
CAGR (3Y)Annualised 3-year return-19.7%+25.4%+58.4%+27.3%+31.5%
TEVA leads this category, winning 3 of 6 comparable metrics.

Risk & Volatility

Evenly matched — TEVA and CAH each lead in 1 of 2 comparable metrics.

CAH is the less volatile stock with a 0.03 beta — it tends to amplify market swings less than TEVA's 1.13 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TEVA currently trades 96.4% from its 52-week high vs TXMD's 68.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricTXMD logoTXMDTherapeuticsMD, I…ANIP logoANIPANI Pharmaceutica…TEVA logoTEVATeva Pharmaceutic…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …
Beta (5Y)Sensitivity to S&P 5000.51x0.63x1.13x0.04x0.03x
52-Week HighHighest price in past year$2.95$99.50$37.35$999.00$233.60
52-Week LowLowest price in past year$0.98$56.71$14.99$637.00$137.75
% of 52W HighCurrent price vs 52-week peak+68.1%+84.3%+96.4%+75.3%+79.3%
RSI (14)Momentum oscillator 0–10043.364.473.516.233.2
Avg Volume (50D)Average daily shares traded21K328K6.6M757K1.7M
Evenly matched — TEVA and CAH each lead in 1 of 2 comparable metrics.

Analyst Outlook

CAH leads this category, winning 2 of 2 comparable metrics.

Analyst consensus: ANIP as "Buy", TEVA as "Buy", MCK as "Buy", CAH as "Buy". Consensus price targets imply 47.8% upside for ANIP (target: $124) vs 8.3% for TEVA (target: $39). For income investors, CAH offers the higher dividend yield at 1.10% vs MCK's 0.36%.

MetricTXMD logoTXMDTherapeuticsMD, I…ANIP logoANIPANI Pharmaceutica…TEVA logoTEVATeva Pharmaceutic…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuy
Price TargetConsensus 12-month target$124.00$39.00$1006.50$249.67
# AnalystsCovering analysts10463133
Dividend YieldAnnual dividend ÷ price+0.1%+0.4%+1.1%
Dividend StreakConsecutive years of raises1011720
Dividend / ShareAnnual DPS$0.05$2.69$2.04
Buyback YieldShare repurchases ÷ mkt cap0.0%+0.7%0.0%+3.4%+1.8%
CAH leads this category, winning 2 of 2 comparable metrics.
Key Takeaway

TXMD leads in 1 of 6 categories (Income & Cash Flow). ANIP leads in 1 (Valuation Metrics). 1 tied.

Best OverallTherapeuticsMD, Inc. (TXMD)Leads 1 of 6 categories
Loading custom metrics...

TXMD vs ANIP vs TEVA vs MCK vs CAH: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is TXMD or ANIP or TEVA or MCK or CAH a better buy right now?

For growth investors, ANI Pharmaceuticals, Inc.

(ANIP) is the stronger pick with 43. 8% revenue growth year-over-year, versus -1. 9% for Cardinal Health, Inc. (CAH). ANI Pharmaceuticals, Inc. (ANIP) offers the better valuation at 25. 3x trailing P/E (9. 2x forward), making it the more compelling value choice. Analysts rate ANI Pharmaceuticals, Inc. (ANIP) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — TXMD or ANIP or TEVA or MCK or CAH?

On trailing P/E, ANI Pharmaceuticals, Inc.

(ANIP) is the cheapest at 25. 3x versus Teva Pharmaceutical Industries Limited at 30. 0x. On forward P/E, ANI Pharmaceuticals, Inc. is actually cheaper at 9. 2x.

03

Which is the better long-term investment — TXMD or ANIP or TEVA or MCK or CAH?

Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +286.

9%, compared to -96. 3% for TherapeuticsMD, Inc. (TXMD). Over 10 years, the gap is even starker: MCK returned +348. 1% versus TXMD's -99. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — TXMD or ANIP or TEVA or MCK or CAH?

By beta (market sensitivity over 5 years), Cardinal Health, Inc.

(CAH) is the lower-risk stock at 0. 03β versus Teva Pharmaceutical Industries Limited's 1. 13β — meaning TEVA is approximately 3238% more volatile than CAH relative to the S&P 500. On balance sheet safety, TherapeuticsMD, Inc. (TXMD) carries a lower debt/equity ratio of 26% versus 2% for Teva Pharmaceutical Industries Limited — giving it more financial flexibility in a downturn.

05

Which is growing faster — TXMD or ANIP or TEVA or MCK or CAH?

By revenue growth (latest reported year), ANI Pharmaceuticals, Inc.

(ANIP) is pulling ahead at 43. 8% versus -1. 9% for Cardinal Health, Inc. (CAH). On earnings-per-share growth, the picture is similar: ANI Pharmaceuticals, Inc. grew EPS 419. 2% year-over-year, compared to 14. 9% for McKesson Corporation. Over a 3-year CAGR, ANIP leads at 40. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — TXMD or ANIP or TEVA or MCK or CAH?

ANI Pharmaceuticals, Inc.

(ANIP) is the more profitable company, earning 8. 9% net margin versus -123. 9% for TherapeuticsMD, Inc. — meaning it keeps 8. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ANIP leads at 12. 6% versus -270. 3% for TXMD. At the gross margin level — before operating expenses — TXMD leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is TXMD or ANIP or TEVA or MCK or CAH more undervalued right now?

On forward earnings alone, ANI Pharmaceuticals, Inc.

(ANIP) trades at 9. 2x forward P/E versus 19. 3x for McKesson Corporation — 10. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ANIP: 47. 8% to $124. 00.

08

Which pays a better dividend — TXMD or ANIP or TEVA or MCK or CAH?

In this comparison, CAH (1.

1% yield), MCK (0. 4% yield) pay a dividend. TXMD, ANIP, TEVA do not pay a meaningful dividend and should not be held primarily for income.

09

Is TXMD or ANIP or TEVA or MCK or CAH better for a retirement portfolio?

For long-horizon retirement investors, Cardinal Health, Inc.

(CAH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 03), 1. 1% yield, +160. 8% 10Y return). Both have compounded well over 10 years (CAH: +160. 8%, TEVA: -28. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between TXMD and ANIP and TEVA and MCK and CAH?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: TXMD is a small-cap high-growth stock; ANIP is a small-cap high-growth stock; TEVA is a mid-cap quality compounder stock; MCK is a mid-cap high-growth stock; CAH is a mid-cap quality compounder stock. CAH pays a dividend while TXMD, ANIP, TEVA, MCK do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

TXMD

High-Growth Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 21%
  • Net Margin > 6%
Run This Screen
Stocks Like

ANIP

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Net Margin > 5%
Run This Screen
Stocks Like

TEVA

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 5%
Run This Screen
Stocks Like

MCK

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Dividend Yield > 0.5%
Run This Screen
Stocks Like

CAH

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Dividend Yield > 0.5%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform TXMD and ANIP and TEVA and MCK and CAH on the metrics below

Revenue Growth>
%
(TXMD: 43.3% · ANIP: 29.6%)
Net Margin>
%
(TXMD: 10.8% · ANIP: 8.9%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.